Astellas Pharma Global Development
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Astellas Pharma Global Development sits in the top decile of US sponsors by registered trial count (#172 of 15,742 sponsors by registered trial count).
Astellas Pharma Global Development: 168 sponsored US clinical trials, 19 recruiting.
Astellas Pharma Global Development sponsors 168 registered US clinical trials on ClinicalTrials.gov, 19 of them currently recruiting, and 121 completed. 28 of these trials are in Phase 3-4 (later-stage) and 132 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy Volunteers, with 10 trials.
Top-decile sponsor footprint
Astellas Pharma Global Development ranks in the top decile of sponsors by registered trial count (#172 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
121 of 139 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (87.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
168 total, page 1 of 4
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
NCT07566156
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
NCT07488676
A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
NCT07566052
A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder
NCT07475806
A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults
NCT07425574
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
NCT07409272
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
NCT07287995
A Study to Learn How Fluconazole, Carbamazepine and Itraconazole Affect How the Body Processes ASP3082 in Healthy Adults
NCT07395024
A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer
NCT07024615
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
NCT07140016
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
NCT07005154
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
NCT06901531
A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy
NCT06779773
A Study to Evaluate the Effects of ASP5502 in Healthy Adults and Adults With Primary Sjögren's Syndrome
NCT06544642
A Study of ASP1002 in Adults for Treatment of Solid Tumors
NCT05719558
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
NCT05365581
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
NCT05083481
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
NCT04729114
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
NCT02960022
A Study of Zolbetuximab With Chemotherapy in Adults With Pancreatic Cancer
NCT06396091
A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats
NCT06049797
A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia
NCT05520567
Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer
NCT04223856
A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
NCT04225117
A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer
NCT03816163
A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).
NCT03653507
A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer
NCT03505320
A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.
NCT03504397
A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer
NCT03288545
Experiment to Assess Preferences for Novel Hormonal Therapy and Androgen-deprivation Therapy in Prostate Cancer Patients
NCT06500741
A Study of ASP1012 in Adults With Solid Tumors
NCT06171178
A Study to Find Out if ASP5354 Can Clearly Help Show the Ureter During Surgery in People With or Without Kidney Disease
NCT05999747
A Study to Find Out if ASP5354 Can Clearly Help Show the Ureter During Surgery
NCT05754333
A Study of ASP2074 in Adults With Solid Tumors
NCT05646797
Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy
NCT05536297
A Study About How ASP5354 Affects the Body in Healthy Adults and in Adults Whose Kidneys do Not Work Well
NCT05495581
A Study to Find a Suitable Dose of ASP8731 and Check for Medical Problems at Each Dose in Healthy Adults
NCT05167526
A Study to Learn How [14C]ASP0367 is Processed by the Body in Healthy Men
NCT05217901
Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants
NCT04939701
A Study of ASP0367 in People With Kidneys That do Not Work Well and in Healthy People
NCT05117294
A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)
NCT05014139
Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen
NCT04837196
A Study to Evaluate ASP0367 in Participants With Mild/Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function
NCT04942964
Survey Based Discrete Choice Experiment Study in Prostate Cancer (DECIDER) Study
NCT05381311
A Study to Evaluate ASP0367 in Participants With Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction
NCT04855201
A Study to Investigate the Effect of Severe Renal Impairment on Gilteritinib Compared to Healthy Participants With Normal Renal Function
NCT04699877
A Study to Assess the Effect of Food With Fezolinetant in Healthy Female Participants
NCT04641260
A Study to Assess ASP0598 Otic Solution Following Topical Application in the Ear in Subjects With Chronic Tympanic Membrane Perforation (CTMP)
NCT04305184
A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
NCT04240002
A Study to Investigate the Effect of Mild and Moderate Hepatic Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Hepatic Function
NCT04482270
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 105 |
| Phase 2 | 27 |
| Phase 3 | 22 |
| Phase 4 | 6 |
Therapeutic Areas
What is open in the Astellas Pharma Global Development pipeline
19 recruiting of 168 indexed (11% open); 121 completed (72%).
Phase mix: 28 late (III/IV) vs 132 early (I/II) (early-phase heavy).
Top condition: Healthy Volunteers (10 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Astellas Pharma Global Development: open-pipeline peers nationwide
Peers matched on 168 registered trials and 11% open enrollment, not the therapeutic-area sidebar.
Astellas Pharma Global Development sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 168 trials (± recruiting share)
- Bausch Health Americas · 168 trials · 4% recruiting
- Seattle Children's Hospital · 168 trials · 17% recruiting
- Sumitomo Pharma America · 168 trials · 4% recruiting
- University of New Mexico · 168 trials · 1% recruiting
Sponsors near 11% open enrollment (± trial volume)
- St. Louis University · 11% recruiting · 107 trials
- University of Connecticut · 11% recruiting · 107 trials
- Children's Mercy Hospital Kansas City · 11% recruiting · 184 trials
- Albert Einstein College of Medicine · 11% recruiting · 175 trials
Related
What to do with this Astellas Pharma Global Development page
168 registered trials is a research-attention snapshot, not an endorsement of Astellas Pharma Global Development or any single study.
- 19 of Astellas Pharma Global Development's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Healthy Volunteers is the condition Astellas Pharma Global Development studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy Volunteers trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Astellas Pharma Global Development pipeline card: 168 registered trials from official public datasets.Report a data error.